Novo Nordisk's golden goose is about to lay a cheaper egg.
Dr. Reddy's is an Indian drug maker. It said it will launch a generic Ozempic in Canada within days. It is the first crack in the patent wall around the most lucrative drug in modern medicine.
Health Canada gave the green light on April 28. Dr. Reddy's was first. Apotex, a Canadian generic maker, got the same nod that day.
That made Canada the first G7 nation to clear a copy of Ozempic. The G7 is the group of seven big rich nations - the US, UK, Japan, Germany, France, Italy, and Canada.
The OK covers the 2 mg and 4 mg pens. Those are used for a once-a-week shot for type 2 diabetes.
It is the same dose patients now pay full price for under the brand name. Canada matters because it is the second-biggest market for the drug, behind only the US.
That means Dr. Reddy's gets a real sales line, and Canadian payers finally get a cheaper option.
For investors trying to track the GLP-1 money trail, Market Briefs breaks down the moves Wall Street is watching every weekday morning - and you get a free investing class when you sign up.
Ozempic and sister drug Wegovy have driven Novo Nordisk's stock for years. The Danish drug maker built one of Europe's biggest firms on the back of semaglutide.
Generic rivals tend to push prices down 50% or more in the first year. In Canada, that math now hits a market that has long pushed back on the brand's price.
The US is a different game. The patents there don't run out until later this decade.
Until that day, generic makers can't sell in the US. So Canada is the test case for how fast the GLP-1 cash machine slows once the gates open.
Novo Nordisk has tried to fight the patent fight in court. So far, none of those moves have held back the Canadian launch.
The drug maker has also pushed its newer pill form of semaglutide to keep brand sales strong. That pill is still patent-locked for now.
Eli Lilly is in the same fight on the other side of the brand. Its drug Zepbound goes after the same weight-loss market. Both firms have a few more years of US patent cover before they face the same kind of pressure.
Dr. Reddy's has been one of the better generic-maker stories of the year. India's drug exporters have spent the past decade building the capacity that was always going to pay off in moments like this.
The big question isn't whether the generic gets sold. It's how fast Canadian doctors switch their scripts over once the price gap is plain.
Watch the first few weeks of sales data. That will tell us how fast the switch starts.
Whichever drug maker captures that switch wins a slice of one of the biggest patent cliffs ahead.
If you want to know what Wall Street is making of moves like this one, join the 350,000+ investors reading Market Briefs - the daily email comes with a 45-minute investing course bundled in.
